Company Quick10K Filing
Cure Pharmaceutical
10-Q 2020-09-30 Filed 2020-11-13
10-Q 2020-06-30 Filed 2020-08-14
10-Q 2020-03-31 Filed 2020-05-15
10-K 2019-12-31 Filed 2020-03-30
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-08-14
10-Q 2019-03-31 Filed 2019-05-20
10-K 2018-12-31 Filed 2019-04-01
10-Q 2018-09-30 Filed 2018-11-14
S-1 2018-07-09 Public Filing
10-Q 2018-06-30 Filed 2018-08-20
10-Q 2018-03-31 Filed 2018-05-15
10-K 2017-12-31 Filed 2018-03-26
10-Q 2017-09-30 Filed 2017-11-14
10-Q 2017-06-30 Filed 2017-08-14
10-Q 2017-03-31 Filed 2017-05-15
10-K 2016-12-31 Filed 2017-04-17
10-Q 2016-09-30 Filed 2016-11-07
10-Q 2016-06-30 Filed 2016-08-15
10-K 2016-03-31 Filed 2016-06-24
10-Q 2015-12-31 Filed 2016-02-04
10-Q 2015-09-30 Filed 2015-11-03
8-K 2020-10-30 Enter Agreement, Leave Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2020-10-23 Officers
8-K 2020-10-21 Leave Agreement
8-K 2020-10-02 Enter Agreement, M&A, Sale of Shares, Officers, Exhibits
8-K 2020-09-25 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2020-09-23 Shareholder Vote
8-K 2020-09-23 Enter Agreement, Sale of Shares, Other Events, Exhibits
8-K 2020-07-27 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2020-06-05
8-K 2020-05-08
8-K 2020-01-10
8-K 2019-11-18
8-K 2019-11-09
8-K 2019-09-30
8-K 2019-08-06
8-K 2019-05-15
8-K 2019-05-14
8-K 2019-04-30
8-K 2019-04-05
8-K 2019-03-29
8-K 2019-01-29
8-K 2019-01-16
8-K 2018-12-26
8-K 2018-12-17
8-K 2018-11-21
8-K 2018-11-15
8-K 2018-10-15
8-K 2018-09-04
8-K 2018-01-22

Cure Pharmaceutical Financials

CURR Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Exagen (XGN) 182,113 54% -60.9 -3% 92,744 34,094 10,439 5,656 -3,141 -2,132 129,862
Soliton (SOLY) 179,964 -14.9 -130% 9,927 2,745 0 0 -12,896 -11,529 171,255
Acro Biomedical (ACBM) 177,190 10% -1,443.4 -13% 1,081 133 3,760 388 -142 -123 177,189
Energy & Technology (ENGT) 177,150 32% -1,446.0 -4% 3,954 9,029 3,101 984 -143 -122 177,039
Kraig Biocraft Laboratories (KBLB) 176,366 -99.2 -224% 899 5,504 0 0 -2,009 -1,775 176,083
American BriVision (ABVC) 175,304 97% -71.6 -38% 7,405 6,675 602 584 -2,817 -2,434 174,252
Vaneck Merk Gold Trust (OUNZ) 175,193 8.4 12% 174,523 0 0 0 20,914 20,914 175,193
Invesco DB Gold Fund (DGL) 174,116 9.8 10% 174,089 3,964 0 0 17,743 17,748 174,116
Fulcrum Therapeutics (FULC) 173,470 -2.4 -26% 115,956 13,828 0 0 -29,711 -29,711 70,781
MariMed (MRMD) 172,389 39% 23.2 -2% 137,056 54,263 40,412 15,889 -2,498 9,162 212,127
Fortem Resources (FTMR) 191,211 -119.9 -1% 143,155 18,644 0 0 -1,741 -1,603 192,221
Cure Pharmaceutical (CURR) 171,305 94% -10.1 -60% 34,029 20,673 284 266 -20,482 -16,320 165,597
FC Global Realty (FCRE) 170,563 86% -62.4 -2% 134,314 52,885 44 38 -2,748 -2,732 170,584
Applied Therapeutics (APLT) 170,485 -5.6 -75% 37,264 6,517 0 0 -27,880 -27,880 157,420
SWK Holdings (SWKH) 167,159 0% 9.7 6% 247,535 19,907 21,396 0 15,043 16,831 162,673
DOCASA (DCSA) 166,631 24% -117.8 -8% 22,047 6,626 6,454 1,527 -1,773 -1,408 165,842
Jamba (JMBA) 165,009 0% 68.1 -4% 36,654 46,912 78,265 0 -1,563 2,289 155,914
QNB (QNBC) 162,260 5.6 1% 1,245,863 1,126,878 0 0 11,939 25,390 141,473
Diverse Development Group (DDG) 161,311 -3,433.4 -24,302% 0 174 0 0 -43 -47 161,311
Gold Reserve (GDRZF) 161,165 -8.9 -15% 78,340 104,144 0 0 -11,575 -11,575 103,488

Balance Sheet ($'000)2015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash1865001,1064612781281088411613035012,5947,6456,258
Accounts Receivable738132144066710301559
Inventory112081791048945701009338404978
PP&E577603713533253163373293113133002971,116659
Assets2415141002,8352,6753,4393,0882,1003,8772,9773,0343,3965,30135,34734,029
Accounts Payable000265294417465545559601745774862539655
Long-Term Debt7001,3001,9003,9254,4355,0005,5753,050550550
Liabilities5441181,1181,1472,4293,2734,0895,7896,4738,1668,5525,45625,25420,673
Stockholders' Equity-1-81,7171,5291,010-185-2,036-1,952-3,529-5,154-5,172-16510,09313,356
Income Statement ($'000)2015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue20380323974351051888874108102
Cost of Revenue00010364059465970423115
Gross Profit20370-4-115-1146118467210787
R&D220206240762427564292361733453
SG&A4831782,4034,5891,291261,0192,0342,4442,3653,0112,217
Tax000000000000
Net Income-2-8-1-11-8-2,620-2,541-1,809-1,180-1,909-2,40213,408-10,035-12,6512,204
Cash Flow ($'000)2015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-920-110-596-1,480-795-685-1,154-1,113-866-1,024-3,528-1,754
Cash Investing-2000-35-29-4016-22-49-52-447,713395
Cash Financing007-0-141,3266856491,9084831,0593,162866-27